Vor Biopharma (VOR) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 30, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 3 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about VOR filings

Are insiders buying or selling Vor Biopharma Inc (VOR) stock?

Neither. Vor Biopharma Inc (VOR) insiders filed no open-market purchases or sales in the 90 days to Oct 30, 2026, according to SEC Form 4 filings.

Which members of Congress have traded VOR recently?

None. No member of Congress disclosed a VOR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this VOR smart-money data?

This summary uses filings available on Oct 30, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on VOR

Lean long1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Politicians
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about VOR filings

Are insiders buying or selling Vor Biopharma Inc (VOR) stock?

Neither. Vor Biopharma Inc (VOR) insiders filed no open-market purchases or sales in the 90 days to Oct 30, 2026, according to SEC Form 4 filings.

Which members of Congress have traded VOR recently?

None. No member of Congress disclosed a VOR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this VOR smart-money data?

Funds

What funds are doing

5 moves · 6 mo

Buys/Adds$168.1M

Buys/Adds (3)

FM
FMR LLC
Q2 2026 13F
$63.3M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
BR
BlackRock
Q2 2026 13F
$49.7M
added
SS
State Street
Q2 2026 13F
$28.2M
added

2 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 2 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Oct 30, 2026

Earnings came in 25.3% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Oct 30, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.90-25.31% miss

-$0.72 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

Estimated report: Nov 12, 2026, in 13 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Oct 30, 2026	-$0.90est. -$0.72	-25.31%miss	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 11, 2026	-$0.80est. -$0.70	-13.97%miss	$0.00Alpha Vantage	No year-ago quarter
Mar 31, 2026Reported May 13, 2026	-$0.73est. -$0.78	+7.22%beat	$0.00Alpha Vantage	No year-ago quarter
Dec 31, 2025Reported Mar 30, 2026	$307.53est. -$1.19	+$308.72beat	$0.00Alpha Vantage	-100.0%from $3.7M
Sep 30, 2025Reported Nov 13, 2025	-$121.63est. -$4.10	-$117.53miss	$0.00Alpha Vantage	No year-ago quarter
Jun 30, 2025Reported Aug 12, 2025	-$251.20est. -$11.80	-$239.40miss	$0.00Alpha Vantage	No year-ago quarter
Mar 31, 2025Reported May 14, 2025	-$5.20est. -$4.16	-25.00%miss	$0.00Alpha Vantage	No year-ago quarter
Dec 31, 2024Reported Mar 20, 2025	-$0.44est. -$0.31	-43.46%miss	$3.7MAlpha Vantage	-69.9%from $12.2M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $19.50
52-wk high: $26.76
High: $20.81
52-wk low: $6.50
Low: $19.28
Prev close: $19.54
Mkt cap: $1.22B
P/E: 0.1x
ROE: -125.4%
Beta: 1.78
P/B: 0.7x
Profit margin: +0.0%
Op margin: +0.0%

Sep 2025 to Jun 2026

What it sold, what it cost, what was left.

RevenueProfit

Sep 2025Dec 2025Mar 2026Jun 2026

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	—	$23.0K	$28.0K	—
Gross profit	—	-$23.0K	-$28.0K	—
What it spent
Research and development	$14.1M	$19.2M	$17.6M	$25.9M
Sales and adminSelling, general and administrative	$14.4M	$16.8M	$17.5M	$21.9M
Other operating costsOperating costs not itemised in the filing's summary	-$451.0K	—	—	—
Total operating expenses	$28.1M	$36.0M	$35.1M	$47.9M
What was left
Operating profitOperating income	-$28.1M	-$36.0M	-$35.2M	-$47.9M
Profit before tax	-$812.7M	$1.72B	-$219.6M	-$62.8M
Net profitNet income	-$812.7M	$1.72B	-$219.6M	-$62.8M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$812.7M	$1.72B	-$219.6M	-$47.8M

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

80 / 100

RSI 14

60balanced

20D volatility

58%annualized

52-week range

$20.65

$6.50$26.76

20D support

$17.70recent floor

20D resistance

$20.81recent ceiling

Returns

5D +9.0%20D +8.2%60D -7.2%

Price vs moving averages

SMA20 +9.2%SMA50 -1.1%SMA200 +19.5%

Volume pace

0.60xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Oct 30, 2026

-$0.90est. -$0.72

-25.31%

$0.00Yahoo Finance

No year-ago quarter

Jun 30, 2026Aug 11, 2026

-$0.80est. -$0.70

-13.97%

$0.00Alpha Vantage

No year-ago quarter

Mar 31, 2026May 13, 2026

-$0.73est. -$0.78

+7.22%

$0.00Alpha Vantage

No year-ago quarter

Dec 31, 2025Mar 30, 2026

$307.53est. -$1.19

+$308.72

$0.00Alpha Vantage

-100.0%from $3.7M

Sep 30, 2025Nov 13, 2025

-$121.63est. -$4.10

-$117.53

$0.00Alpha Vantage

No year-ago quarter

Jun 30, 2025Aug 12, 2025

-$251.20est. -$11.80

-$239.40

$0.00Alpha Vantage

No year-ago quarter

Mar 31, 2025May 14, 2025

-$5.20est. -$4.16

-25.00%

$0.00Alpha Vantage

No year-ago quarter

Dec 31, 2024Mar 20, 2025

-$0.44est. -$0.31

-43.46%

$3.7MAlpha Vantage

-69.9%from $12.2M

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	—	$23.0K	$28.0K	—
Gross profit	—	-$23.0K	-$28.0K	—
What it spent
Research and development	$14.1M	$19.2M	$17.6M	$25.9M
Sales and adminSelling, general and administrative	$14.4M	$16.8M	$17.5M	$21.9M
Other operating costsOperating costs not itemised in the filing's summary	-$451.0K	—	—	—
Total operating expenses	$28.1M	$36.0M	$35.1M	$47.9M
What was left
Operating profitOperating income	-$28.1M	-$36.0M	-$35.2M	-$47.9M
Profit before tax	-$812.7M	$1.72B	-$219.6M	-$62.8M
Net profitNet income	-$812.7M	$1.72B	-$219.6M	-$62.8M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$812.7M	$1.72B	-$219.6M	-$47.8M

USD

Sep 2025

Dec 2025

Mar 2026

Jun 2026

What came in

RevenueTotal revenue

Cost of what it soldCost of revenue

—

$23.0K

$28.0K

—

Gross profit

—

-$23.0K

-$28.0K

—

What it spent

Research and development

$14.1M

$19.2M

$17.6M

$25.9M

Sales and adminSelling, general and administrative

$14.4M

$16.8M

$17.5M

$21.9M

Other operating costsOperating costs not itemised in the filing's summary

-$451.0K

—

Total operating expenses

$28.1M

$36.0M

$35.1M

$47.9M

What was left

Operating profitOperating income

-$28.1M

-$36.0M

-$35.2M

-$47.9M

Profit before tax

-$812.7M

$1.72B

-$219.6M

-$62.8M

Net profitNet income

-$812.7M

$1.72B

-$219.6M

-$62.8M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$812.7M

$1.72B

-$219.6M

-$47.8M

Vor Biopharma Inc

Smart money at a glance

What do analysts expect?

Questions about VOR filings

Smart money on VOR

Questions about VOR filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 25.3% below what analysts expected.

Estimated report: Nov 12, 2026, in 13 days

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Vor Biopharma Inc

Smart money at a glance

What do analysts expect?

Questions about VOR filings

Smart money on VOR

Questions about VOR filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 25.3% below what analysts expected.

Estimated report: Nov 12, 2026, in 13 days

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Vor Biopharma Inc

Overview

Questions about VOR filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Vor Biopharma Inc

Overview

Questions about VOR filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.